On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Pressure BioSciences Inc. (PBIO) Gains Praise Amid Disclosure of Innovative Research Tool to Aid Gynecological Cancer Diagnosis, Therapy

  • Pressure BioSciences was described as an integral part of women’s cancer research efforts during a presentation last month at the International Gynecologic Cancer Society conference in Brazil
  • The company’s patented pressure cycling technology provided a key link in a trio of procedures for analyzing biopsied cells
  • Gynecologic cancers are diagnosed in the United States at a rate of nearly 100,000 women per year, and the global gynecological cancer drug market is expected to generate revenues of more than $41.8 billion by 2026

A new, novel workflow for the analysis of proteins from cancer biopsy samples was recently disclosed at a major international gynecologic cancer meeting. This innovative workflow is expected to markedly enhance cancer diagnosis, prognosis and effective treatment therapies. The revelation of this new workflow has augmented the reputation of Pressure BioSciences Inc. (OTCQB: PBIO) amid the modern science rush to build better precision medicine for malignancies that claim hundreds of thousands of lives each year in the United States alone (http://ibn.fm/vawZS).

Human biology is complex, but scientific advances in the field of big data analysis have provided remarkably advanced tools for attempting repairs on the constellation of minuscule pieces of the human machine that may break down.

Efforts to develop an optimal means of analyzing proteins from cancer biopsy samples led one group of top gynecologic researchers to a new, innovative workflow that utilizes Pressure BioSciences’ patented pressure cycling technology (PCT) platform as the bridging mechanism in a process that begins with Leica Microsystems’ laser microdissection (LMD) platform and ends with comprehensive analysis on a ThermoFisher Scientific mass spectrometry (MS) instrument.

Pressure BioSciences’ PCT platform, as an integral part of the analytical trio, prepares the excised cells for micro-scale quantitative proteomics and phosphoproteomics – the large-scale study of proteins and their phosphorylation-based signaling networks – by provoking rapid and efficient high-quality cellular protein release and preparation from the biopsy samples. The entire sample preparation process is done in the company’s proprietary Barocycler 2320EXT system.

The researchers presented an explanation of their working process in searching for ways to combat gynecological cancers during a core session of the annual International Gynecologic Cancer Society (“IGCS”) conference last month in Rio de Janeiro, Brazil. Dr. Larry Maxwell, a gynecologic oncologist and the OB-GYN chairman at Northern Virginia’s Inova Fairfax Hospital, described the PCT-based Barocycler system technology provided by Pressure BioSciences as “an essential requirement for our novel workflow in meeting our goals” in his presentation to the IGCS.

“The conventional use of chemotherapy in ovarian cancer treatment is being rapidly replaced by biologic therapeutics that target the cancer (the ‘seed’) and also the micro-environment (the ‘soil’) in which it grows,” Maxwell stated in a news release (http://ibn.fm/fo6x7). “Being able to collect small tissue specimens and characterize them across multiple genomic and proteomic platforms will enable us to markedly enhance our ability to develop companion diagnostics and prognostics as well as identify targets for future therapeutic strategies.”

Protein chemist Dr. Thomas Conrads, the senior director of women’s health research at the Inova Women’s Hospital, added, “We believe that the insights we gain from applying this novel workflow will result in significant improvements in the clinical management of gynecologic cancer.”

Gynecologic cancers are diagnosed at a rate of nearly 100,000 women per year in the United States (http://ibn.fm/koVZR). Aurora Healthcare estimates that more than 30,000 of those patients die each year (http://ibn.fm/EezJZ). Publication The Pharma Letter, citing analysis by Persistence Market Research Report, states that the worldwide market for gynecological cancer drugs is expected to expand at a CAGR of 6.2 percent between 2018 and 2026, generating revenues of more than $41.8 billion (http://ibn.fm/aeE8t), with most of the costs led by the United States. The importance of effective therapies in terms of life-saving measures and product costs is apparent, and it serves as an indicator of PBIO technology’s potential attractiveness to other research labs.

Pressure BioSciences continues adding a number of significant achievements to underscore the reputation of its technology. Recently, the company announced an agreement with a world-renowned, multibillion-dollar biotherapeutics firm that will use PBIO’s proprietary BaroFold(TM) technology to improve the manufacture of a protein drug (http://ibn.fm/KaqJ1). Protein-based therapeutics are a growing part of the global health care industry, which is projected to reach nearly $249 billion in revenues by next year, according to Research and Markets analysis (http://ibn.fm/RIKAI).

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered